Novel Antibody Obliterates Psoriasis

July 9, 2014 9:00 PM

8 0

Treatment of longstanding moderate-to-severe plaque psoriasis with the monoclonal antibody secukinumab was associated with rapid and dramatic improvements, two large phase III clinical trials found.

In one study, known as ERASURE, improvements of 75% on the Psoriasis Area and Severity Index (PASI 75) were seen at 3 months in 81.6% of patients receiving 300 mg secukinumab and in 71.6% of those given 150 mg, compared with 4.5% of those randomized to placebo (P<0.001 for both), according to Richar...

Read more

To category page